• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Pharmacogenetics of therapies in rheumatoid arthritis.
【24h】

Pharmacogenetics of therapies in rheumatoid arthritis.

机译：类风湿关节炎的药物遗传学。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Rheumatoid arthritis (RA) is an inflammatory, aggressive arthritis causing irreversible joint destruction and damage when left untreated. Disease-modifying antirheumatic drugs (DMARDs) are the mainstay of treatment for RA and ameliorate not only the clinical signs and symptoms but also joint damage associated with the disease. In recent years, biological therapies have been introduced for the treatment of RA, and the effectiveness of these agents in slowing the clinical and radiographic progression in RA has been established beyond question. However, there is significant variability in the response of patients with RA to these therapies. Moreover, the biological therapies are expensive, totaling several thousand dollars in yearly patient costs. Pharmacogenomics, the study of genetic variations in drug-metabolizing enzymes and their translation to differential responses to drugs, is a nascent but rapidly evolving field. The application of pharmacogenomics to therapies used in RA, particularly the new expensive biological agents, holds great promise for tailoring therapy with these agents based on a patient's genetics. Published literature on the pharmacogenetics of commonly used DMARDs and the emerging body of literature on the pharmacogenetics of the new biological therapies in RA are the focus of this review. As evident from the contents of this review, pharmacogenomics is an exciting field which is progressing productively and rapidly. Pharmacogenomic approaches offer powerful tools to optimize drug therapy in individual patients.
机译：类风湿关节炎（RA）是一种炎症性侵袭性关节炎，如果不加以治疗，会引起不可逆的关节破坏和损害。改变疾病的抗风湿药（DMARDs）是RA的主要治疗手段，不仅可以改善临床症状和体征，还可以改善与疾病相关的关节损伤。近年来，已经引入了用于治疗RA的生物疗法，并且毫无疑问地确定了这些药物在减缓RA的临床和放射学进展方面的有效性。但是，RA患者对这些疗法的反应存在显着差异。而且，生物疗法很昂贵，每年的患者总费用为几千美元。药物基因组学是研究药物代谢酶的遗传变异及其将其转化为对药物的不同反应的研究，是一个新兴但发展迅速的领域。药物基因组学在RA中使用的疗法中的应用，尤其是在新的昂贵的生物制剂中，对于根据患者的遗传学定制这些药物的疗法具有广阔的前景。本研究的重点是已发表的有关常用DMARDs药物遗传学的文献以及有关RA中新生物疗法的药物遗传学的新兴文献。从本综述的内容可以明显看出，药物基因组学是一个令人兴奋的领域，正在迅速而高效地发展。药物基因组学方法为优化个别患者的药物治疗提供了强大的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号